Please assess the completion status of the following clinical trial:

Trial Title: Nitroglycerin in Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-small cell lung cancer stage IB-IV amenable for radiotherapy with curative intent.~* (Stage IV patients with oligometastic (1-4 metastases) NSCLC are regularly treated radically in the IKNL region).~* Patients not included in the PET-Boost or the Lucanix trial.~* WHO performance status 0-2.~* Willing and able to comply with the study prescriptions.~* 18 years or older.~* Ability to give and having given written informed consent before patient registration.~* No recent (\< 3 months) severe cardiac disease (NYHA class \>1) (congestive heart failure, infarction).~* No radiotherapy in 4 weeks prior to this study.~* No treatment with investigational drugs in 4 weeks prior to or during this study.~* No known allergy to nitroglycerin or nitroglycerin patch.~* No known allergy to iodine based contrast agents~* No use of Levitra, Viagra or Cialis at the time of application of the nitroglycerin patch.~* No conditions necessitating the use of ergot alkaloids, alpha blockers (eg tamsulosine), betablockers or calcium channel blockers on the day of nitroglycerin patch application).~* No other active malignancy.~* No major surgery (excluding diagnostic procedures like eg mediastinoscopy) in previous 4 weeks.~* Adequate renal function: calculated creatinine clearance at least 60ml/min.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nitroglycerin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).